ライフサイエンスコーパス: smoker

1 vey of 1,521 adults (301 combustible tobacco smokers).

2 ted OR, 0.70; 95% CI, 0.56-0.86) than former smokers.

3 mortality and CVD risk but only among never smokers.

4 ncer mortality among male former and current smokers.

5 sociated with respiratory disease in at-risk smokers.

6 t in the bronchoalveolar lavage of cigarette smokers.

7 igher incidence of esophageal cancer in male smokers.

8 ers squared), and 49% were current or former smokers.

9 (+) CD8 T cells were observed only in HIV(+) smokers.

10 with a different contour pattern than never-smokers.

11 3 than healthy sites in both smokers and non-smokers.

12 reater in current smokers compared to former smokers.

13 droxycotinine/cotinine), but only in current smokers.

14 VD and mortality were only observed in never smokers.

15 okers is two to three times as high as never smokers.

16 oss all conditions, compared to non-ADHD non-smokers.

17 1.71 (95% CI: 0.95, 3.09; p = 0.07) in never smokers.

18 e predominantly lower socioeconomic position smokers.

19 All participants were non-smokers.

20 ogic types and lung cancer in ever and never smokers.

21 urrent smokers and 56% (n = 6013) were never-smokers.

22 nd 19 313 (29%) of 66 316 women were current smokers.

23 e prevalent among all adults but lower among smokers.

24 c cancer in racial and ethnic minorities and smokers.

25 e pulmonary disease (COPD), even among never-smokers.

26 former and current smokers, but not in never-smokers.

27 emained when limiting analyses to noncurrent smokers.

28 ne intake and subsequent PD risk among never-smokers.

29 , hawthorn and fermented bean curd) than non-smokers.

30 lso enable investigation of never and former smokers.

31 (95% CI: 1.12, 1.43; p = 0.002) among never smokers.

32 tients with STEMI, 1,093 (42.6%) were recent smokers.

33 dless of smoking history, including in never-smokers.

34 study in 58,000 European or African ancestry smokers.

35 a and air trapping increased over 5 years in smokers.

36 pulmonary perfusion abnormalities similar to smokers.

37 alian non-mentholated 7 mg ISO tar cigarette smokers.

38 1-3 when compared with diseased sites of non-smokers.

39 females (52.9%), and 164 (30.9%) were active smokers.

40 5%) had early COPD, of whom 58% were current smokers.

41 , and 40.8% were men, and 29.0% were current smokers.

42 d from periodontally healthy smokers and non-smokers.

43 lose a decade of life expectancy versus non-smokers.

44 silicotics and in current, former, and never-smokers.

45 the excess risk of death compared to current smokers.

46 CT-quantified emphysema and air trapping in smokers.

47 ecedents (120 European American [23% current smokers], 101 African American [26% current smokers]) we

48 2%] of 196 patients), were current or former smokers (159 [81%] of 196), had non-small-cell lung canc

49 bstruction (63.3% vs 36.7%, P = 0.01), to be smokers (17% vs 6.9%, P = 0.04), and had a higher ECV (3

50 moking on the periodontium compared to never-smokers; (2) patterns of site-specific effects by age am

51 y (GCD) was measured in 71 current or former smokers [32 subjects without COPD and 39 COPD subjects].

52 PM3 level was higher for exclusive cigarette smokers (39.8 mug/g creatinine) than for non-users (3.05

53 8, 95% 1.00-3.62), being a current or former smoker (4.24, 1.70-12.95), receiving treatment with chem

54 01), male (77.0% vs. 61.4.0%, p < 0.05), and smokers (44.3% vs. 13.4%, p < 0.001).

55 Younger adults were more frequently smokers (52% vs. 38% vs. 22%, respectively) and obese (4

56 1 alcoholic drink per week or current/former smokers; 6) with no health condition.

57 mia cases with IDU occurred more commonly in smokers (68.8% vs 18.5%; RR, 3.7 [95% CI, 3.1-4.4]), tho

58 +/- 221.4 cm; 23.7% had diabetes, 13.9% were smokers, 68.7% were recurrent, and 23.6% incarcerated.

59 ing cessation when trials were restricted to smokers (9 trials, n = 2516; 80.7% vs 84.1% continued sm

60 .5 times more likely to be current or former smokers (95% CI: 2.3-2.7) than Afghan SIVH.

61 ork compared brain TSPO levels in 20 tobacco smokers (abstinent for at least 2 h) and 20 nonsmokers u

62 Smokers also had a reduced CV(2) (Qvgrad)/CV(2) (Qtotal)

63 Fourteen smoker and 13 non-smoker patients completed the study pr

64 lpha-1 antitrypsin concentrations in a heavy smoker and chronic obstructive pulmonary disease cohort,

65 e more consistently significant in the never-smoker and non-alcohol drinking groups.

66 Analysis of palatal tissues from 12 non-smokers and 10 smokers identified 830 significantly (P <

67 age II subjects with COPD and as controls 20 smokers and 11 nonsmokers with normal lung function.

68 Forty patients with periodontitis, 20 smokers and 20 non-smokers were recruited.

69 overall sample, 19% (n = 2015) were current smokers and 56% (n = 6013) were never-smokers.

70 12 human donors without pulmonary disease (6 smokers and 6 nonsmokers) were evaluated using design-ba

71 reased, more teeth/sites were affected among smokers and by the 5th decade nearly all teeth/sites had

72 pathogens and NK cell function is altered in smokers and COPD.

73 n right anterior insula and right putamen in smokers and decreased dorsal anterior cingulate cortex a

74 These findings may partly explain why smokers and elderly persons with compromised surfactant

75 old more frequent in ex-smokers than current smokers and had considerably longer telomeres than their

76 efractory nature of respiratory illnesses in smokers and highlight cigarette smoking as a potential d

77 Tobacco smokers and males are overrepresented.

78 stase capacity did not differ between former smokers and never-smokers (P = 0.67).Conclusions: SZ nev

79 nd selected inflammatory mediators levels in smokers and non-smokers was also evaluated.

80 ing analysis of the tracheal epithelium from smokers and non-smokers, we generate a comprehensive atl

81 levels of HNP 1-3 than healthy sites in both smokers and non-smokers.

82 ts, were obtained from periodontally healthy smokers and non-smokers.

83 Infarct size was similar in smokers and nonsmokers (adjusted difference: 0.0%; 95% c

84 (11)C-PBR28 volumes of distribution between smokers and nonsmokers (whole-brain Cohen d = 0.09) desp

85 P2A6, and CYP2A7 (and CYP1A2) mRNA levels in smokers and nonsmokers were assessed in Gene Expression

86 Methods: We used PET/CT in 46 smokers and nonsmokers, 23 of whom had documented HIV in

87 eolar lavage of HIV-infected and -uninfected smokers and nonsmokers.

88 Nor was the extent of MVO different between smokers and nonsmokers.

89 were defined in nondiseased human lungs from smokers and nonsmokers.

90 posed facade among subpopulations of current smokers and obese individuals.

91 e a relevant impact on health outcomes among smokers and on health care system expenditures.

92 Current smokers and past smokers have higher IOP than patients w

93 erium that commonly colonizes the airways of smokers and patients with chronic lung disease, can caus

94 AMs from smokers and subjects with COPD display increased express

95 u Biobank Cohort Study, after excluding ever smokers and those with poor health, 19,405 Chinese (50+

96 not be an effective cessation aid for adult smokers and, instead, may contribute to continuing nicot

97 ients were divided into current smoker, past smoker, and never smoker categories.

98 n-Hispanic black, 67% were former or current smokers, and 56% reported ever having anal sex with a ma

99 eripheral blood NK cells from never smokers, smokers, and COPD patients and employed a non-supervised

100 ever, more than 25% of COPD patients are non-smokers, and gene-by-smoking interactions are expected t

101 ility to pulmonary infections in smokers, ex-smokers, and vulnerable populations exposed to secondhan

102 ay a role in ACE2 upregulation in the SAE of smokers; and 5) ACE2 is expressed in airway epithelium d

103 Our results suggest that male smokers are at increased risk of left colon cancer and f

104 creased risk of left colon cancer and female smokers are at increased risk of right colon cancer.

105 Up to two-thirds of deaths among smokers are avoidable at non-smoking death rates, and fo

106 Cannabis users who are also tobacco smokers are more likely to exhibit cannabis dependence a

107 Since the offspring of smokers are more likely to smoke than the offspring of n

108 her, these results may partially explain why smokers are particularly susceptible to severe SARS-CoV-

109 he progression of expiratory air trapping in smokers are scarce.

110 This difference is much stronger in smokers as compared to nonsmokers.

111 cept for the higher plaque scores in the non-smokers at 6 months (P <0.01).

112 -negative bacteria were more abundant in the smokers at baseline and so were Gram-positive bacteria i

113 The CXR-LC model identified smokers at high risk for incident lung cancer, beyond CM

114 on chest radiograph images may identify more smokers at high risk for lung cancer who could benefit f

115 In current smokers, at least 25% of cells carried driver mutations

116 re endorsed, with just 16% of adults (12% of smokers) believing smoking was uncommon.

117 age older than 40 years, female sex, current smoker, body mass index 30 or greater, and a hernia-rela

118 he risk of lung cancer in former and current smokers, but not in never-smokers.

119 years, comparing never-smokers with current smokers by age they started smoking and number of cigare

120 ber of cigarettes smoked per day and with ex-smokers by the age at which they had quit.

121 into current smoker, past smoker, and never smoker categories.

122 associated with anthracosis in lungs of non-smokers (coefficient = 6.0; standard error = 2.9; p = 0.

123 Log(10)GCD was greater in current smokers compared to former smokers.

124 age and fewer cardiovascular risk factors in smokers compared with nonsmokers.

125 in smokers without COPD when compared to non-smoker control participants but did not correlate with s

126 stal bone loss [CBL]) are worse in cigarette-smokers (CS) and patients with type-2 diabetes mellitus

127 and compared with the profiles of cigarette smokers (CS), dual users, and non-users.

128 Compared with never smokers, current and past smokers showed a statistically

129 ver-smokers (P = 0.67).Conclusions: SZ never-smokers demonstrated no increased risk of COPD, regardle

130 kers (NS), CS, EC, and dual EC and cigarette smokers (DS).

131 Amongst smokers, e-cigarette mean puff volumes (41.6 mL vs 41.3

132 characterized by a high percentage of never-smokers, early onset and predominant EGFR mutations.

133 gy of COPD study evaluated current or former smokers enrolled between 2008 and 2011 who did not meet

134 ke was maintained among the subgroup of male smokers even with adjustment for the depth and amount of

135 ed susceptibility to pulmonary infections in smokers, ex-smokers, and vulnerable populations exposed

136 The same was found among non-smokers except an inverse association was found between

137 However, smokers exhibit faster repopulation of Gram-negative bac

138 ients with distant metastasis and found that smokers exhibited a significantly high incidence of brai

139 Gram-negative bacteria repopulated in the smokers faster than in the non-smokers (P <0.01).

140 Compared with male smokers, female smokers had a greater increase in risk o

141 Among never-smokers, fewer teeth/sites were affected with PD > 2.1 m

142 After removing smokers from the training set, the MRS strongly associat

143 ing topography measurements observed between smokers (Group 1) and regular vapers/dual users (Group 2

144 1.03, 95% CI: 0.89, 1.18), while female ever smokers had a 20% higher risk (HR = 1.20, 95% CI: 1.06,

145 ith never smokers of the same sex, male ever smokers had a 39% higher risk (hazard ratio (HR) = 1.39,

146 Compared with male smokers, female smokers had a greater increase in risk of rectal cancer

147 r adjustment for age and other risk factors, smokers had a similar 1-year risk of death (adjusted haz

148 Lungs from chronic smokers had increased IM numbers and overall density, su

149 ared with nonsmokers, subjects with COPD and smokers had increased numbers of bronchial mucosal monoc

150 Results showed that current smokers had lower BMI and consumed foods less frequently

151 Smokers had lower crude 1-year rates of all-cause death

152 Smokers had lower lung CYP2A mRNA levels compared with n

153 Current smokers had more affected teeth and/or periodontal sites

154 y better responses (P < 0.02); likewise, non-smokers had similarly better response (P < 0.02).

155 About a third of current cigarette smokers had started before age 15 years.

156 are male, aged < 65 years, current or former smokers, had no CNS or liver metastasis, had not EGFR mu

157 3]) were older, were more likely to be ever smokers, had shorter peripheral blood mononuclear cell t

158 dable at non-smoking death rates, and former smokers have about only a quarter of the excess risk of

159 These findings suggest that nonsmokers and smokers have comparable TSPO levels in the brain.

160 One third of healthy smokers have detectable imaging changes, suggesting a ne

161 Current smokers and past smokers have higher IOP than patients who never smoked.

162 e values to classify tobacco use showed that smokers have higher serum concentrations of six terpenes

163 An increase in MS lesions was mainly seen in smokers; however, this VRF is most likely to be present

164 xposed) as well as adult (N = 207; 57 active smokers) human postmortem prefrontal cortices.

165 f palatal tissues from 12 non-smokers and 10 smokers identified 830 significantly (P <0.05) different

166 ally representative cohort of 2,535 adult US smokers in 2014-2015 (baseline assessment), who, in 2015

167 Evaluating predictive epigenomic marks of smokers in peripheral blood may allow for targeted risk

168 ciations with lung function among continuous smokers in the Lung Health Study (United States and Cana

169 There is some evidence that smokers - in particular, women - who endorse stronger no

170 We randomized 40 SCZ non-smokers into a double-blind clinical trial with four gro

171 Mortality among current smokers is two to three times as high as never smokers.

172 terstitial changes in the lung parenchyma of smokers, known as Interstitial Lung Abnormalities (ILA),

173 nce in CV(2) (Qvgrad)/CV(2) (Qtotal) between smokers living with and without HIV (0.39 vs. 0.34, P =

174 ed vertical perfusion gradient (Qv(grad)) in smokers living with HIV.

175 rategies for management of early stage never-smoker lung adenocarcinoma.

176 Results A total of 175 ex-smokers (mean age, 69 years +/- 9 [standard deviation],

177 Among smokers, mean packs/day was 0.60 (95% CI = 0.44-0.77) at

178 Among ever smokers (median pack-years: 20, males; 12, females), AO

179 +/- 12.7 years; 47% men; 28.4% current or ex-smokers; median duration of diabetes 4 [IQR: 1-9] years;

180 ting 101 deaths among 667 current and former smokers.Methods: We assayed genome-wide DNA methylation

181 ify how this is altered in chronic cigarette smokers.Methods: Whole right upper lobes from 12 human d

182 ed (Glycine vs. No Glycine carriers) current smokers (n = 104, >= 10 cigarettes per day).

183 btained from asymptomatic ART-treated HIV(+) smokers (n = 11) and nonsmokers (n = 15) and uninfected

184 e the effects of nicotine dependence (trait; smokers (n = 24) vs. non-smoking controls; n = 20) and a

185 date of the NMR in European ancestry current smokers (n = 5185), found 1255 genome-wide significant v

186 d NLST (National Lung Screening Trial) heavy smokers (n = 5493, 6-year follow-up).

187 XR-LC model was validated in additional PLCO smokers (n = 5615, 12-year follow-up) and NLST (National

188 = 11) and nonsmokers (n = 15) and uninfected smokers (n = 7) and nonsmokers (n = 10).

189 Non-smokers needing two implants in different quadrants were

190 oportions of cases were older, male, current smokers, nonaspirin users, and had lower BMIs, compared

191 er risk of overweight or obesity for current smokers, normal weight individuals were found to have th

192 id (GCF) levels of MT in smokers (S) and non-smokers (NS) with chronic periodontitis (CP), and compar

193 h type-2 diabetes mellitus (T2DM) than never-smokers (NS) without T2DM.

194 participants consisting of four groups, non-smokers (NS), CS, EC, and dual EC and cigarette smokers

195 ferent in EC and DS groups compared with non-smokers (NS).

196 ere affected with PD > 2.1 mm, whereas among smokers, number of affected teeth/sites increased with a

197 nancy; or uterine abnormality and/or current smoker of tobacco.

198 Groups 1 and 3 included adult smokers of 7 mg ISO tar tobacco cigarettes, and Group 2

199 ng cancer screening, particularly by current smokers of a low socioeconomic position, compromises eff

200 ox regression models, as compared with never smokers of the same sex, male ever smokers had a 39% hig

201 current smoking (9.4%, vs. 5.6% among former smokers or nonsmokers; odds ratio, 1.79; 95% CI, 1.29 to

202 = 1.17, 1.01-1.35) and lung cancer in never smokers (OR = 1.56, 1.05-2.30).

203 rrent (OR = 1.71, 95% CI = 1.24-2.31) and ex-smokers (OR = 2.83, 95% CI = 2.14-3.72) were considerabl

204 ulated in the smokers faster than in the non-smokers (P <0.01).

205 nd so were Gram-positive bacteria in the non-smokers (P <0.01).

206 not differ between former smokers and never-smokers (P = 0.67).Conclusions: SZ never-smokers demonst

207 participants (P for trend = 0.006), and ever-smokers (P for trend = 0.0005).

208 ctive smoking status, pack-years, years as a smoker, packs smoked per day, and hours as a passive smo

209 The current study was based on never-smoker participants from 2 large prospective cohorts: th

210 Patients were divided into current smoker, past smoker, and never smoker categories.

211 Fifteen healthy and non-smoker patients (nine males and six females; mean age: 4

212 Fourteen smoker and 13 non-smoker patients completed the study protocol and reveale

213 Smoker patients with non-small cell lung cancer (NSCLC)

214 The present findings suggest that smoker patients with periodontitis Stage III and IV, Gra

215 packs smoked per day, and hours as a passive smoker per week.

216 igher in lung tumors from smokers than never-smokers, pointing toward the mutagenic activity of the S

217 tiative for Obstructive Lung Disease stage 0 smokers predicted structural and physiologic disease pro

218 Diseased sites of smokers presented significantly lower levels of LL-37 an

219 ypertensive, diabetic, hepatitis C positive, smokers, Public Health Service - Increased Risk designat

220 Among smokers recently diagnosed with cancer in 2 National Can

221 2,197 (10.8%) and 9,423 (15.8) were current smokers, respectively.

222 rom human epithelial brushes (smoker vs. non-smoker) revealed a high degree of similarity between der

223 -analysis showed an increased risk of IFD in smokers (RR 1.41 [95% confidence interval 1.09-1.81]; P

224 gival crevicular fluid (GCF) levels of MT in smokers (S) and non-smokers (NS) with chronic periodonti

225 The smoker's paradox may be explained by the younger age and

226 rt-term outcomes, an observation termed the "smoker's paradox." It has been postulated that smoking m

227 Smokers scored higher for the ROS signature, which predi

228 Among current smokers, several teeth/sites were affected (CAL>=2.1 mm)

229 Smokers should be advised to stop smoking to limit type

230 indings fit a recent proposal that abstinent smokers show decreased ability to divert cognitive resou

231 ompared with never smokers, current and past smokers showed a statistically significantly higher IOP

232 d for inhibitory control was high, abstinent smokers showed no deficits.

233 By contrast, acutely abstinent smokers showed performance deficits in easier conditions

234 ndence and smoking-related diseases in human smokers.SIGNIFICANCE STATEMENT Allelic variation in CHRN

235 notyped peripheral blood NK cells from never smokers, smokers, and COPD patients and employed a non-s

236 een smoking habits (focusing on the age when smokers started) and cause-specific premature mortality

237 rse self-reported health, back pain and stop-smoker status.

238 l frontal gyrus in both healthy subjects and smokers, suggesting that value-based decision-making can

239 ociation with PTSD is most pronounced in non-smokers, suggesting the result was independent of smokin

240 moking may cause suppression of appetite but smokers tend to have other unhealthy habits relating to

241 Heavy smokers tended to have drinking habits, which was associ

242 obesity, diabetes, and be current or former smokers than Afghan SIVH.

243 processes, were fourfold more frequent in ex-smokers than current smokers and had considerably longer

244 s in the brain (measured as SUV) for tobacco smokers than for nonsmokers by demonstrating the importa

245 on signature were higher in lung tumors from smokers than never-smokers, pointing toward the mutageni

246 Terpene concentrations were 14-78% higher in smokers than nonusers.

247 y abnormal changes in the lung parenchyma of smokers that might overlap chronic obstructive pulmonary

248 or vaping products, and exclusive cigarette smokers that was initiated in 2015.

249 Compared with never-smokers, the all-cause mortality RR was highest in parti

250 Among smokers, there were no clear associations between any of

251 cific effects by age among current and never-smokers using contour maps.

252 Smokers versus nonsmokers (from GSE30063 and GSE108134)

253 ed 1) the levels of human lung CYP2A mRNA in smokers versus nonsmokers and 2) the impact of daily nic

254 36% to 56% greater in the lungs of cigarette smokers versus nonsmokers.Conclusions: The precise locat

255 prevalent, with 60-77% of adults (17-48% of smokers) viewing smoking as something of which others di

256 ex (1.63, 1.07-2.48), smoking status (former smoker vs never smoked: 1.60, 1.03-2.47), number of como

257 shed data set from human epithelial brushes (smoker vs. non-smoker) revealed a high degree of similar

258 ammatory mediators levels in smokers and non-smokers was also evaluated.

259 : No difference between SZ and control never-smokers was seen.

260 -specific ageing-related increase among ever smokers was strongly related to cumulative tobacco expos

261 difference in IOP between current and never smokers was the highest in the fourth decade, regardless

262 the tracheal epithelium from smokers and non-smokers, we generate a comprehensive atlas of epithelial

263 Smokers were 10 years younger and had fewer comorbiditie

264 ossover design was used in which healthy non-smokers were administered placebo and nicotine (2-mg loz

265 all airway epithelia (SAE) of nonsmokers and smokers were analyzed for expression of ACE2 and other c

266 Exclusive tobacco smokers were distinguished from non-users using a combin

267 Most affected sites for current smokers were interproximal sites of most posterior teeth

268 Current smokers were less likely to attend (adjusted OR, 0.70; 9

269 and Brown, living in urban areas and current smokers were more likely to have vitamin D insufficiency

270 ts with periodontitis, 20 smokers and 20 non-smokers were recruited.

271 smokers], 101 African American [26% current smokers]) were analyzed.

272 s in ASXL1 are enriched in current or former smokers, whereas cancer therapy with radiation, platinum

273 Smokers who endorsed stronger descriptive non-smoking no

274 Female (but not male) past-year smokers who endorsed stronger injunctive (OR(adj) = 2.19

275 Furthermore, smokers who quit before pregnancy, regardless of smoking

276 The 21(st) century hazards reveal that smokers who start smoking early in adult life and do not

277 Smokers who switch completely to e-cigarettes may reduce

278 pare long-term abstinence between matched US smokers who tried to quit with and without use of e-ciga

279 Among US smokers who used e-cigarettes to help quit, 12.9% (95% c

280 Most cigarette smokers who wish to quit too often relapse within the fi

281 istration was significantly higher among non-smokers with ADHD, and their choices of nicotine were no

282 Materials and Methods Cigarette smokers with and those without COPD participating in the

283 e-wide DNA methylation in non-Hispanic white smokers with and without chronic obstructive pulmonary d

284 Materials and Methods Current and former smokers with and without chronic obstructive pulmonary d

285 icipants who are current or former cigarette smokers with and without chronic obstructive pulmonary d

286 ation associated with all-cause mortality in smokers with and without COPD.

287 Background Smokers with chronic obstructive pulmonary disease (COPD

288 rtality at ages 30-69 years, comparing never-smokers with current smokers by age they started smoking

289 Smokers with ENP demonstrated age-associated increases i

290 urvive in the ROS-rich TME and suggests that smokers with lung cancer may benefit from therapies usin

291 Overall, 3,042 (71.7%) were ever-smokers with mean tobacco exposure of 33 pack-years.

292 SuStaIn placed 30% of smokers with normal lung function at elevated stages, su

293 a marker to predict EGFR TKI sensitivity in smokers with NSCLC carrying EGFR(WT) and that the combin

294 that the primary determinant of GCH in ever smokers with or without airflow obstruction is active sm

295 etric response map (mPRM) measurements in ex-smokers with or without COPD by using volume-matched CT

296 st CT (FVC/TLC(CT)) among current and former smokers with PRISm (FEV(1)/FVC >= 0.7 and FEV1 < 80%) in

297 ged 60 to 75 years, 2) recorded as a current smoker within the last 7 years, and 3) no prespecified e

298 Ex-smokers without COPD had a larger fraction of normal mPR

299 were higher in participants with COPD and in smokers without COPD when compared to non-smoker control

300 P < .001), both of which were present in ex-smokers without COPD.